Coloplast Valuation
Is CBH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CBH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CBH (€11.9) is trading below our estimate of fair value (€20.37)
Significantly Below Fair Value: CBH is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CBH?
Key metric: As CBH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CBH's PE Ratio? | |
|---|---|
| PE Ratio | 39.7x |
| Earnings | DKK 5.05b |
| Market Cap | DKK 200.37b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.2x |
| Enterprise Value/EBITDA | 27.1x |
| PEG Ratio | 3.1x |
Price to Earnings Ratio vs Peers
How does CBH's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 21x | ||
PHH2 Paul Hartmann | 11.7x | n/a | €713.9m |
SHL Siemens Healthineers | 28.3x | 14.2% | €55.0b |
AFX Carl Zeiss Meditec | 25.5x | 16.3% | €5.2b |
FME Fresenius Medical Care | 18.6x | 19.3% | €12.2b |
CBH Coloplast | 39.7x | 12.9% | €200.4b |
Price-To-Earnings vs Peers: CBH is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the peer average (21x).
Price to Earnings Ratio vs Industry
How does CBH's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: CBH is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the European Medical Equipment industry average (29.7x).
Price to Earnings Ratio vs Fair Ratio
What is CBH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 39.7x |
| Fair PE Ratio | 29.7x |
Price-To-Earnings vs Fair Ratio: CBH is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the estimated Fair Price-To-Earnings Ratio (29.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Ship Healthcare Holdings
JP¥196.5b
Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.
5EZ
JP¥12.40
7D
-3.1%
1Y
-4.6%
Sensus Healthcare
US$125.2m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$7.25
7D
16.0%
1Y
272.6%
CVS Health
US$66.9b
Provides health solutions in the United States.
CVS
US$53.25
7D
2.4%
1Y
-14.7%